Oxford University COVID-19 vaccine Phase II trials positive

Oxford University COVID-19 vaccine Phase II trials positive.

According to the latest results published in “The Lancet” magazine, the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 in the United Kingdom is shown to be equivalent to adults aged 18-55 in healthy elderly (56 years and older). Safety and immunogenicity.

The Phase II clinical trial found that the vaccine does not cause side effects in all age groups and at low and standard doses.

T cell response (i.e. cellular immune response, which can find and attack virus-infected cells) within 14 days after the first dose of vaccination, and antibody response (i.e. humoral immune response, which Can detect and attack viruses as they spread).

Phase 3 trials are currently underway to confirm these results and the effectiveness of the vaccine in preventing SARS-CoV-2 infection, which is applicable to a wider population, including elderly people with basic health conditions.

The lead author of the study, Professor Andrew Pollard of the University of Oxford in the United Kingdom, said: “Because the immune system of the elderly gradually deteriorates with age, the immune response of vaccines usually decreases, which also makes the elderly more susceptible to infection. “

Co-author Dr. Mahesh Ramasamy from the University of Oxford in the United Kingdom added: “In our study, the elderly showed strong antibody and T cell responses after vaccination.

We hope that our vaccine will help protect some of the most vulnerable in society. Population, but further research is needed before we can determine it.”

This new study is the fifth public clinical trial of the SARS-CoV-2 vaccine tested in the adult population. It has also been shown that other COVID-19 vaccines can produce an immune response in the elderly, but it is difficult to compare the results between different studies.

In the Phase 2 trial released today, 560 participants (160 18-55 years old, 160 56-69 years old, 240 70 years old or older) were divided into 10 groups and received low-dose ChAdOx1 nCoV. -19 vaccine or standard dose, or control vaccine (meningococcal conjugate vaccine).

Participants over 55 years of age were also divided into several groups and received a single dose of the vaccine or two vaccinations with an interval of 28 days.

Before vaccination, all participants had to undergo blood tests to determine whether they had previously been infected with SARS-CoV-2. People with SARS-CoV-2 antibodies were excluded.

Participants aged 18-55 who have received two standard doses of Oxford COVID-19 vaccine and all participants aged 56 years or older are on the day of vaccination, 1 after the first and second vaccination. Immune response assessments were performed at 2 and 4 weeks.

The results showed that the adverse reactions of the ChAdOx1 nCoV-19 vaccine were mild (the most common effects were pain and tenderness at the injection site, fatigue, headache, fever and muscle pain), but more common than the control vaccine. In the six months since the first dose was administered, 13 serious adverse events occurred, none of which were related to vaccination.

Oxford University COVID-19 vaccine Phase II trials positive

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.